cormedix - CRMD

CRMD

Close Chg Chg %
12.48 -0.85 -6.81%

Closed Market

11.63

-0.85 (6.81%)

Volume: 3.60M

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: cormedix - CRMD

CRMD Key Data

Open

$12.40

Day Range

11.62 - 12.45

52 Week Range

5.60 - 17.43

Market Cap

$916.32M

Shares Outstanding

78.79M

Public Float

69.21M

Beta

1.36

Rev. Per Employee

N/A

P/E Ratio

6.08

EPS

$2.26

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.69M

 

CRMD Performance

1 Week
 
-7.18%
 
1 Month
 
10.13%
 
3 Months
 
2.56%
 
1 Year
 
43.58%
 
5 Years
 
56.53%
 

CRMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About cormedix - CRMD

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CRMD At a Glance

CorMedix, Inc.
300 Connell Drive
Berkeley Heights, New Jersey 07922
Phone 1-908-517-9500 Revenue 43.47M
Industry Biotechnology Net Income -17,930,020.00
Sector Health Technology Employees 65
Fiscal Year-end 12 / 2025
View SEC Filings

CRMD Valuation

P/E Current 6.079
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 10.969
Price to Book Ratio 6.163
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -19.439
Enterprise Value to Sales 9.792
Total Debt to Enterprise Value 0.001

CRMD Efficiency

Revenue/Employee 668,802.615
Income Per Employee -275,846.462
Receivables Turnover 0.842
Total Asset Turnover 0.433

CRMD Liquidity

Current Ratio 3.386
Quick Ratio 3.161
Cash Ratio 1.527

CRMD Profitability

Gross Margin 92.661
Operating Margin -51.427
Pretax Margin -44.453
Net Margin -41.245
Return on Assets -17.849
Return on Equity -23.165
Return on Total Capital -21.051
Return on Invested Capital -23.037

CRMD Capital Structure

Total Debt to Total Equity 0.611
Total Debt to Total Capital 0.607
Total Debt to Total Assets 0.435
Long-Term Debt to Equity 0.412
Long-Term Debt to Total Capital 0.41
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cormedix - CRMD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- 190.94K 65.41K 43.47M
Sales Growth
- -20.19% -65.74% -100.00%
Cost of Goods Sold (COGS) incl D&A
210.83K 212.77K 205.56K 3.19M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
177.02K 209.04K 205.56K 457.36K
Depreciation
177.02K 209.04K 205.56K 301.52K
Amortization of Intangibles
- - - 155.84K
-
COGS Growth
-39.48% +0.92% -3.39% +1,452.10%
Gross Income
(19.89K) (147.36K) (205.56K) 40.28M
Gross Income Growth
+81.77% -640.82% -39.49% +19,695.86%
Gross Profit Margin
- -10.42% -225.30% +92.66%
2021 2022 2023 2024 5-year trend
SG&A Expense
29.42M 30.48M 48.75M 62.64M
Research & Development
13.13M 10.68M 13.16M 3.94M
Other SG&A
16.28M 19.80M 35.60M 58.70M
SGA Growth
+8.51% +3.60% +59.97% +28.48%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(29.44M) (30.62M) (48.96M) (22.36M)
Non Operating Income/Expense
(6.89K) 363.16K 2.62M 3.07M
Non-Operating Interest Income
14.40K 326.02K 2.68M 2.58M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 15.94K 26.52K 36.41K
Interest Expense Growth
- -52.02% +66.31% -100.00%
Gross Interest Expense
- 15.94K 26.52K 36.41K
Interest Capitalized
- - - -
-
Pretax Income
(29.46M) (30.29M) (46.34M) (19.32M)
Pretax Income Growth
-8.32% -2.81% -53.00% +58.30%
Pretax Margin
- -15,429.47% -46,305.23% -44.45%
Income Tax
- (1.25M) (585.62K) (1.39M)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(28.21M) (29.70M) (46.34M) (17.93M)
Minority Interest Expense
- - - -
-
Net Income
(28.21M) (29.70M) (46.34M) (17.93M)
Net Income Growth
-28.07% -5.29% -56.02% +61.31%
Net Margin Growth
- -14,774.70% -45,409.90% -41.24%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(28.21M) (29.70M) (46.34M) (17.93M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(28.21M) (29.70M) (46.34M) (17.93M)
EPS (Basic)
-0.749 -0.7375 -0.9103 -0.3046
EPS (Basic) Growth
+2.88% +1.54% -23.43% +66.54%
Basic Shares Outstanding
37.67M 40.27M 50.90M 58.87M
EPS (Diluted)
-0.749 -0.7375 -0.9103 -0.3046
EPS (Diluted) Growth
+2.88% +1.54% -23.43% +66.54%
Diluted Shares Outstanding
37.67M 40.27M 50.90M 58.87M
EBITDA
(29.26M) (30.41M) (48.75M) (21.90M)
EBITDA Growth
-8.06% -3.95% -60.29% +55.08%
EBITDA Margin
- -15,324.80% -46,500.32% -50.37%

Snapshot

Average Recommendation BUY Average Target Price 19.00
Number of Ratings 7 Current Quarters Estimate 0.668
FY Report Date 03 / 2026 Current Year's Estimate 2.541
Last Quarter’s Earnings 0.92 Median PE on CY Estimate N/A
Year Ago Earnings 2.719 Next Fiscal Year Estimate 2.218
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 7 5
Mean Estimate 0.67 0.68 2.54 2.22
High Estimates 0.72 0.72 3.40 3.28
Low Estimate 0.62 0.64 1.27 0.77
Coefficient of Variance 10.95 8.78 25.65 43.25

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cormedix - CRMD

Date Name Shares Transaction Value
Nov 20, 2025 Janet D. Dillione Director 48,473 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.42 per share 553,561.66
Apr 4, 2025 Steven W. Lefkowitz Director 120,498 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.03 per share 485,606.94
Apr 4, 2025 Steven W. Lefkowitz Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Joseph Todisco Chief Executive Officer; Director 530,721 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.38 per share 1,793,836.98
Apr 2, 2025 Joseph Todisco Chief Executive Officer; Director 440,830 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Cormedix in the News